Clinical Observation of Montelukast Combined with Moxifloxacin in the Treatment of Cough of Acute Bac-terial Bronchitis
10.6039/j.issn.1001-0408.2017.29.17
- VernacularTitle:孟鲁司特联合莫西沙星治疗急性细菌性支气管炎咳嗽的临床观察
- Author:
Long WANG
1
;
Qunli DING
;
Hongying MA
;
Xiaofei LIANG
;
Zaichun DENG
Author Information
1. 宁波市鄞州区钱湖医院内科
- Keywords:
Acute bacterial bronchitis;
Cough;
Montelu-kast;
Moxifloxacin
- From:
China Pharmacy
2017;28(29):4096-4099
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe clinical efficacy and safety of montelukast combined with moxifloxacin in the treatment of cough of acute bacterial bronchitis. METHODS:A total of 139 cases of cough of acute bacterial bronchitis selected from out-patient department of Ningbo Yinzhou District Qianhu Hospital during Jan.-Dec. 2016 were divided into control group(69 cases) and observation group(70 cases)according to random number table. Control group was given Moxifloxacin hydrochloride tab-lets 0.4 g,po,qd;observation group was additionally given Montelukast sodium tablets 10 mg,po,once every night,on the basis of control group. Both groups were treated for 6 d. Cough symptom scores,peripheral blood WBC and CRP contents were compared between 2 groups before and after treatment. Clinical efficacies,the occurrence of ADR and clinical outcome were ob-served in 2 groups. RESULTS:Before treatment,there was no statistical significance in cough symptom scores,peripheral blood WBC or CRP contents between 2 groups(P>0.05). Compared to before treatment,cough symptom scores,peripheral blood WBC and CRP contents of 2 groups were decreased significantly after treatment,and the cough symptom score of observa-tion group after 3 d of treatment was significantly lower than that of control group at the same time,with statistical significance (P<0.05). There was no statistical significance in above indexes between 2 groups after 6 d of treatment(P>0.05). Cure rate of observation group was 64.29%,which was significantly higher than 44.93% of control group,with statistical significance (P<0.05). Response rates of observation group and control group were 97.14% and 97.10%,there was no statistical signifi-cance(P>0.05). No ADR was found in 2 groups during treatment,and good clinical outcome was obtained. CONCLUSIONS:Montlukast combined with moxifloxacin not only relieve cough symptom and inflammation,but also improve cure rate significantly with good safety.
